Citadel Advisors
ADIL

Citadel Advisors’s Adial Pharmaceuticals ADIL Stock Holding History

Citadel Advisors’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,785
Closed -$48.3K – 12872
2025
Q4 		$48.3K Buy
8,785
+3,033
+53% +$24.6K ﹤0.01% 12053
2025
Q3 		$50.8K Buy
+5,752
New +$56.1K ﹤0.01% 12196
2025
Q1 		– Sell
-2,180
Closed -$55.1K – 14378
2024
Q4 		$55.1K Buy
2,180
+849
+64% +$22.1K ﹤0.01% 12294
2024
Q3 		$33.2K Buy
1,331
+341
+34% +$8.89K ﹤0.01% 12335
2024
Q2 		$28.5K Buy
+990
New +$37.4K ﹤0.01% 12319
2022
Q4 		– Sell
-424
Closed -$93K – 14822
2022
Q3 		$93K Buy
+424
New +$191K ﹤0.01% 11150
2021
Q3 		– Sell
-32
Closed -$52K – 13721
2021
Q2 		$52K Sell
32
-87
-73% -$132K ﹤0.01% 13321
2021
Q1 		$180K Sell
119
-4
-3% -$6.04K ﹤0.01% 11826
2020
Q4 		$131K Buy
+123
New +$145K ﹤0.01% 10033
2019
Q2 		– Sell
-42
Closed -$91K – 9094
2019
Q1 		$91K Buy
+42
New +$125K ﹤0.01% 8589

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Citadel Advisors's ADIL Position: Q1 2026 in Review

Citadel Advisors sold out of Adial Pharmaceuticals (ADIL) in Q1 2026, closing a stake of 8,785 shares — an estimated $48.3K sold.

Citadel Advisors first reported a position in ADIL in Q1 2019 and held it in 10 quarters. The position peaked at $180K in Q1 2021. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • Citadel Advisors reported no remaining Adial Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 8,785 Adial Pharmaceuticals shares in Q1 2026, an estimated $48.3K.
  • Citadel Advisors first reported a position in Adial Pharmaceuticals in Q1 2019 and held it in 10 quarters.
  • Citadel Advisors's Adial Pharmaceuticals position peaked at $180K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.